UY36401A - Conjugados anticuerpos-fármacos - Google Patents
Conjugados anticuerpos-fármacosInfo
- Publication number
- UY36401A UY36401A UY0001036401A UY36401A UY36401A UY 36401 A UY36401 A UY 36401A UY 0001036401 A UY0001036401 A UY 0001036401A UY 36401 A UY36401 A UY 36401A UY 36401 A UY36401 A UY 36401A
- Authority
- UY
- Uruguay
- Prior art keywords
- antibodies
- antibody
- binding fragments
- antigen
- drug
- Prior art date
Links
- 239000000611 antibody drug conjugate Substances 0.000 title abstract 2
- 229940049595 antibody-drug conjugate Drugs 0.000 title abstract 2
- 239000000427 antigen Substances 0.000 abstract 5
- 102000036639 antigens Human genes 0.000 abstract 5
- 108091007433 antigens Proteins 0.000 abstract 5
- 239000012634 fragment Substances 0.000 abstract 4
- 238000000034 method Methods 0.000 abstract 3
- 229940127121 immunoconjugate Drugs 0.000 abstract 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 abstract 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229940039227 diagnostic agent Drugs 0.000 abstract 1
- 239000000032 diagnostic agent Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/77—Internalization into the cell
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Hospice & Palliative Care (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
Esta solicitud describe anticuerpos anti-cadherina-P, fragmentos de unión a antígeno de los mismos, y conjugados de fármaco-anticuerpo de dichos anticuerpos o fragmentos de unión a antígeno. La invención también se refiere a métodos para tratar el cáncer usando los anticuerpos, fragmentos de unión a antígeno, y conjugados de fármacos -anticuerpos. También se describen en este documento procedimientos de preparación de los anticuerpos, fragmentos de unión a antígeno, conjugados de fármacos de anticuerpos, métodos de uso de los anticuerpos y fragmentos de unión a antígeno como agentes de diagnóstico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462079942P | 2014-11-14 | 2014-11-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
UY36401A true UY36401A (es) | 2016-06-30 |
Family
ID=54695810
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UY0001036401A UY36401A (es) | 2014-11-14 | 2015-11-13 | Conjugados anticuerpos-fármacos |
Country Status (25)
Country | Link |
---|---|
US (2) | US10005836B2 (es) |
EP (1) | EP3218410B1 (es) |
JP (1) | JP6831783B2 (es) |
KR (1) | KR20170084202A (es) |
CN (1) | CN108064244B (es) |
AR (1) | AR102649A1 (es) |
AU (1) | AU2015347015B2 (es) |
BR (1) | BR112017009813A2 (es) |
CA (1) | CA2967188A1 (es) |
CL (1) | CL2017001217A1 (es) |
CO (1) | CO2017004782A2 (es) |
CR (1) | CR20170200A (es) |
EA (1) | EA201791050A1 (es) |
EC (1) | ECSP17034845A (es) |
GT (1) | GT201700102A (es) |
IL (1) | IL252015A0 (es) |
MA (1) | MA40913A (es) |
MX (1) | MX2017006301A (es) |
PE (1) | PE20170912A1 (es) |
PH (1) | PH12017500890A1 (es) |
SG (1) | SG11201703464UA (es) |
TN (1) | TN2017000173A1 (es) |
TW (1) | TW201625692A (es) |
UY (1) | UY36401A (es) |
WO (1) | WO2016075670A1 (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20170084202A (ko) * | 2014-11-14 | 2017-07-19 | 노파르티스 아게 | 항체 약물 접합체 |
EP3310813A1 (en) * | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
TWI794171B (zh) | 2016-05-11 | 2023-03-01 | 美商滬亞生物國際有限公司 | Hdac抑制劑與pd-l1抑制劑之組合治療 |
TWI808055B (zh) | 2016-05-11 | 2023-07-11 | 美商滬亞生物國際有限公司 | Hdac 抑制劑與 pd-1 抑制劑之組合治療 |
CA3027181A1 (en) * | 2016-06-08 | 2017-12-14 | Abbvie Inc. | Anti-egfr antibody drug conjugates |
WO2018034354A1 (ja) * | 2016-08-19 | 2018-02-22 | 富士フイルムRiファーマ株式会社 | 緩衝剤を含む組成物 |
CN110139828B (zh) | 2016-08-25 | 2021-05-28 | 豪夫迈·罗氏有限公司 | 多官能化硅纳米颗粒、其制备方法及其在基于电化学发光的检测方法中的用途 |
EP3360898A1 (en) | 2017-02-14 | 2018-08-15 | Boehringer Ingelheim International GmbH | Bispecific anti-tnf-related apoptosis-inducing ligand receptor 2 and anti-cadherin 17 binding molecules for the treatment of cancer |
JOP20190187A1 (ar) | 2017-02-03 | 2019-08-01 | Novartis Ag | مترافقات عقار جسم مضاد لـ ccr7 |
WO2018185618A1 (en) | 2017-04-03 | 2018-10-11 | Novartis Ag | Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment |
WO2019197610A1 (en) * | 2018-04-13 | 2019-10-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | New vaccinal strategy |
KR20220017931A (ko) * | 2019-05-20 | 2022-02-14 | 노파르티스 아게 | Mcl-1 억제제 항체-약물 접합체 및 사용 방법 |
CA3144324A1 (en) * | 2019-06-24 | 2020-12-30 | Novartis Ag | Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen |
WO2021030665A1 (en) * | 2019-08-15 | 2021-02-18 | Silverback Therapeutics, Inc. | Formulations of benzazepine conjugates and uses thereof |
EP4106819A1 (en) | 2020-02-21 | 2022-12-28 | Silverback Therapeutics, Inc. | Nectin-4 antibody conjugates and uses thereof |
KR20230047361A (ko) | 2020-07-01 | 2023-04-07 | 아르스 파마슈티컬스 인크. | 항-asgr1 항체 접합체 및 이의 용도 |
TWI771198B (zh) * | 2020-10-20 | 2022-07-11 | 中央研究院 | 用於檢測生物樣本的檢測方法及檢測系統 |
EP4337702A1 (en) * | 2021-05-13 | 2024-03-20 | Wuxi Biologics Ireland Limited | Antibody conjugate comprising anti-p-cadherin antibody and uses thereof |
US20240052065A1 (en) * | 2022-07-15 | 2024-02-15 | Boehringer Ingelheim International Gmbh | Binding molecules for the treatment of cancer |
Family Cites Families (110)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2429001A (en) | 1946-12-28 | 1947-10-14 | Axel H Stone | Artificial hand |
US2779780A (en) | 1955-03-01 | 1957-01-29 | Du Pont | 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation |
US3720760A (en) | 1968-09-06 | 1973-03-13 | Pharmacia Ab | Method for determining the presence of reagin-immunoglobulins(reagin-ig)directed against certain allergens,in aqueous samples |
US4458066A (en) | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
ATE37983T1 (de) | 1982-04-22 | 1988-11-15 | Ici Plc | Mittel mit verzoegerter freigabe. |
US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
US5128326A (en) | 1984-12-06 | 1992-07-07 | Biomatrix, Inc. | Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same |
US5374548A (en) | 1986-05-02 | 1994-12-20 | Genentech, Inc. | Methods and compositions for the attachment of proteins to liposomes using a glycophospholipid anchor |
MX9203291A (es) | 1985-06-26 | 1992-08-01 | Liposome Co Inc | Metodo para acoplamiento de liposomas. |
WO1988007089A1 (en) | 1987-03-18 | 1988-09-22 | Medical Research Council | Altered antibodies |
US5677425A (en) | 1987-09-04 | 1997-10-14 | Celltech Therapeutics Limited | Recombinant antibody |
US5108921A (en) | 1989-04-03 | 1992-04-28 | Purdue Research Foundation | Method for enhanced transmembrane transport of exogenous molecules |
WO1991005548A1 (en) | 1989-10-10 | 1991-05-02 | Pitman-Moore, Inc. | Sustained release composition for macromolecular proteins |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
AU642932B2 (en) | 1989-11-06 | 1993-11-04 | Alkermes Controlled Therapeutics, Inc. | Protein microspheres and methods of using them |
US5714350A (en) | 1992-03-09 | 1998-02-03 | Protein Design Labs, Inc. | Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
EP0563475B1 (en) | 1992-03-25 | 2000-05-31 | Immunogen Inc | Cell binding agent conjugates of derivatives of CC-1065 |
AU4116793A (en) | 1992-04-24 | 1993-11-29 | Board Of Regents, The University Of Texas System | Recombinant production of immunoglobulin-like domains in prokaryotic cells |
CA2163345A1 (en) | 1993-06-16 | 1994-12-22 | Susan Adrienne Morgan | Antibodies |
GB9323884D0 (en) | 1993-11-19 | 1994-01-05 | Eisai London Res Lab Ltd | Physiological modulation |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US6132764A (en) | 1994-08-05 | 2000-10-17 | Targesome, Inc. | Targeted polymerized liposome diagnostic and treatment agents |
ATE252894T1 (de) | 1995-01-05 | 2003-11-15 | Univ Michigan | Oberflächen-modifizierte nanopartikel und verfahren für ihre herstellung und verwendung |
US5869046A (en) | 1995-04-14 | 1999-02-09 | Genentech, Inc. | Altered polypeptides with increased half-life |
US6121022A (en) | 1995-04-14 | 2000-09-19 | Genentech, Inc. | Altered polypeptides with increased half-life |
AU710347B2 (en) | 1995-08-31 | 1999-09-16 | Alkermes Controlled Therapeutics, Inc. | Composition for sustained release of an agent |
US6169071B1 (en) | 1996-07-12 | 2001-01-02 | Mcgill University | Compounds and methods for modulating cell adhesion |
US6056973A (en) | 1996-10-11 | 2000-05-02 | Sequus Pharmaceuticals, Inc. | Therapeutic liposome composition and method of preparation |
US5895748A (en) | 1996-11-27 | 1999-04-20 | Johnson; Keith R. | Panel of antibodies for detecting cadherins and catenins in tissues and method of using the panel of antibodies |
US6277375B1 (en) | 1997-03-03 | 2001-08-21 | Board Of Regents, The University Of Texas System | Immunoglobulin-like domains with increased half-lives |
JP2002512624A (ja) | 1997-05-21 | 2002-04-23 | バイオベーション リミテッド | 非免疫原性タンパク質の製造方法 |
CA2293632C (en) | 1997-06-12 | 2011-11-29 | Research Corporation Technologies, Inc. | Artificial antibody polypeptides |
US5989463A (en) | 1997-09-24 | 1999-11-23 | Alkermes Controlled Therapeutics, Inc. | Methods for fabricating polymer-based controlled release devices |
SE512663C2 (sv) | 1997-10-23 | 2000-04-17 | Biogram Ab | Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
DK2180007T4 (da) | 1998-04-20 | 2017-11-27 | Roche Glycart Ag | Glycosyleringsteknik for antistoffer til forbedring af antistofafhængig cellecytotoxicitet |
IL124650A0 (en) | 1998-05-26 | 1998-12-06 | Yeda Res & Dev | Methods and therapeutic compositions for treating cancer |
IL143236A0 (en) | 1998-12-16 | 2002-04-21 | Warner Lambert Co | Treatment of arthritis with mek inhibitors |
KR20060067983A (ko) | 1999-01-15 | 2006-06-20 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
EP2275541B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
WO2001005950A2 (en) | 1999-07-20 | 2001-01-25 | Morphosys Ag | Methods for displaying (poly)peptides/proteins on bacteriophage particles via disulfide bonds |
ATE349438T1 (de) | 1999-11-24 | 2007-01-15 | Immunogen Inc | Cytotoxische wirkstoffe enthaltend taxane und deren therapeutische anwendung |
DE60031793T2 (de) | 1999-12-29 | 2007-08-23 | Immunogen Inc., Cambridge | Doxorubicin- und daunorubicin-enthaltende, zytotoxische mittel und deren therapeutische anwendung |
US7700359B2 (en) | 2000-06-02 | 2010-04-20 | Novartis Vaccines And Diagnostics, Inc. | Gene products differentially expressed in cancerous cells |
WO2002006484A1 (fr) | 2000-07-19 | 2002-01-24 | Takara Bio Inc. | Procede de detection de cancer |
ES2461854T3 (es) | 2000-07-19 | 2014-05-21 | Warner-Lambert Company Llc | Ésteres oxigenados de ácidos 4-yodofenilamino-benzhidroxámicos |
AU2001277172A1 (en) | 2000-07-26 | 2002-02-05 | Applied Genomics, Inc. | Bstp-trans protein and related reagents and methods of use thereof |
US6333410B1 (en) | 2000-08-18 | 2001-12-25 | Immunogen, Inc. | Process for the preparation and purification of thiol-containing maytansinoids |
CA2445611A1 (en) | 2001-05-31 | 2002-12-05 | Chiron Corporation | P-cadherin as a target for anti-cancer therapy |
US6441163B1 (en) | 2001-05-31 | 2002-08-27 | Immunogen, Inc. | Methods for preparation of cytotoxic conjugates of maytansinoids and cell binding agents |
AU2002337935B2 (en) | 2001-10-25 | 2008-05-01 | Genentech, Inc. | Glycoprotein compositions |
PL216224B1 (pl) | 2002-02-01 | 2014-03-31 | Ariad Pharmaceuticals | Pochodne rapamycyny zawierające fosfor, kompozycja je zawierająca oraz ich zastosowanie |
WO2003076424A1 (en) | 2002-03-08 | 2003-09-18 | Eisai Co. Ltd. | Macrocyclic compounds useful as pharmaceuticals |
TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
EP1560597A4 (en) | 2002-10-29 | 2007-06-27 | Pharmacia Corp | DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES |
WO2004044000A2 (en) | 2002-11-14 | 2004-05-27 | Adherex Technologies, Inc. | Compounds and methods for modulating functions of classical cadherins |
ATE514713T1 (de) | 2002-12-23 | 2011-07-15 | Wyeth Llc | Antikörper gegen pd-1 und ihre verwendung |
US20040137539A1 (en) | 2003-01-10 | 2004-07-15 | Bradford Sherry A. | Cancer comprehensive method for identifying cancer protein patterns and determination of cancer treatment strategies |
US20040137538A1 (en) | 2003-01-10 | 2004-07-15 | Bradford Sherry A. | Cancer comprehensive assay kit for identifying cancer protein patterns |
WO2004086038A2 (en) | 2003-03-28 | 2004-10-07 | Institut Curie | A method for screening compounds having the capacity to control tumor cell invasion or metastasis using constitutively active akt |
US8088387B2 (en) | 2003-10-10 | 2012-01-03 | Immunogen Inc. | Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates |
WO2005007175A2 (en) | 2003-06-09 | 2005-01-27 | The Brigham And Women's Hospital, Inc. | Cadherin directed molecular and cellular localization |
US7399865B2 (en) | 2003-09-15 | 2008-07-15 | Wyeth | Protein tyrosine kinase enzyme inhibitors |
US20050221398A1 (en) | 2004-01-16 | 2005-10-06 | Ipsogen, Sas, A Corporation Of France | Protein expression profiling and breast cancer prognosis |
WO2005090572A2 (en) | 2004-03-24 | 2005-09-29 | Oncotherapy Science, Inc. | Compositions and methods for treating pancreatic cancer |
US20080008719A1 (en) | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
ES2503719T3 (es) | 2005-02-11 | 2014-10-07 | Immunogen, Inc. | Procedimiento para preparar conjugados de anticuerpos y de maitansinoides |
EP1877444A2 (en) | 2005-04-26 | 2008-01-16 | Pfizer, Inc. | P-cadherin antibodies |
US8603986B2 (en) | 2005-04-28 | 2013-12-10 | Mcgill University | Compounds and methods for modulating cadherin-mediated processes |
NZ563193A (en) | 2005-05-09 | 2010-05-28 | Ono Pharmaceutical Co | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
DK1907424T3 (en) | 2005-07-01 | 2015-11-09 | Squibb & Sons Llc | HUMAN MONOCLONAL ANTIBODIES TO PROGRAMMED death ligand 1 (PD-L1) |
PL1912636T3 (pl) | 2005-07-21 | 2015-02-27 | Ardea Biosciences Inc | N-(aryloamino)sulfonamidowe inhibitory mek |
JP2009506790A (ja) | 2005-09-07 | 2009-02-19 | メディミューン,エルエルシー | 毒素とコンジュゲートしたeph受容体抗体 |
WO2007075672A2 (en) | 2005-12-23 | 2007-07-05 | Lankenau Institute For Medical Research | Prognostic cancer markers |
JO2660B1 (en) | 2006-01-20 | 2012-06-17 | نوفارتيس ايه جي | Pi-3 inhibitors and methods of use |
JP2009528257A (ja) | 2006-02-28 | 2009-08-06 | オンコセラピー・サイエンス株式会社 | 抗cdh3抗体のエフェクター機能を用いて細胞を障害する方法 |
WO2007140371A2 (en) | 2006-05-30 | 2007-12-06 | Genentech, Inc. | Antibodies and immunoconjugates and uses therefor |
US20080026481A1 (en) | 2006-06-16 | 2008-01-31 | Michael Mitas | Molecular based two-marker assays that predict outcome of adenocarcinoma patients |
WO2008104803A2 (en) | 2007-02-26 | 2008-09-04 | Oxford Genome Sciences (Uk) Limited | Proteins |
EP2170959B1 (en) | 2007-06-18 | 2013-10-02 | Merck Sharp & Dohme B.V. | Antibodies to human programmed death receptor pd-1 |
ES2537352T3 (es) | 2007-09-12 | 2015-06-05 | Genentech, Inc. | Combinaciones de compuestos inhibidores de fosfoinositida 3-cinasa y agentes quimioterapéuticos, y metodos para su uso |
WO2009055730A1 (en) | 2007-10-25 | 2009-04-30 | Genentech, Inc. | Process for making thienopyrimidine compounds |
CN101970499B (zh) | 2008-02-11 | 2014-12-31 | 治疗科技公司 | 用于肿瘤治疗的单克隆抗体 |
US8168757B2 (en) | 2008-03-12 | 2012-05-01 | Merck Sharp & Dohme Corp. | PD-1 binding proteins |
US8236319B2 (en) | 2008-04-30 | 2012-08-07 | Immunogen, Inc. | Cross-linkers and their uses |
US8168784B2 (en) | 2008-06-20 | 2012-05-01 | Abbott Laboratories | Processes to make apoptosis promoters |
CA2729403A1 (en) | 2008-06-30 | 2010-01-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
CN102203125A (zh) | 2008-08-25 | 2011-09-28 | 安普利穆尼股份有限公司 | Pd-1拮抗剂及其使用方法 |
SI2350129T1 (sl) | 2008-08-25 | 2015-11-30 | Amplimmune, Inc. | Sestavki PD-1 antagonistov in postopek njihove uporabe |
EP2356270B1 (en) | 2008-11-07 | 2016-08-24 | Fabrus Llc | Combinatorial antibody libraries and uses thereof |
CN108997498A (zh) | 2008-12-09 | 2018-12-14 | 霍夫曼-拉罗奇有限公司 | 抗-pd-l1抗体及它们用于增强t细胞功能的用途 |
JP5844159B2 (ja) | 2009-02-09 | 2016-01-13 | ユニヴェルシテ デクス−マルセイユUniversite D’Aix−Marseille | Pd−1抗体およびpd−l1抗体ならびにその使用 |
CN102753579A (zh) | 2009-05-01 | 2012-10-24 | 国立大学法人东京大学 | 抗钙粘着蛋白抗体 |
US20130017199A1 (en) | 2009-11-24 | 2013-01-17 | AMPLIMMUNE ,Inc. a corporation | Simultaneous inhibition of pd-l1/pd-l2 |
EP3450459B1 (en) * | 2009-12-28 | 2021-05-26 | OncoTherapy Science, Inc. | Anti-cdh3 antibodies and uses thereof |
BR112012020116B8 (pt) | 2010-02-10 | 2023-01-10 | Perseus Proteomics Inc | Anticorpo anti-p-caderina marcado com metal radioativo, agente terapêutico contra o câncer e agente de diagnóstico de câncer que compreendem o dito anticorpo, hibridoma, bem como usos do mesmo para produzir um agente terapêutico contra o câncer e um agente de diagnóstico de câncer |
JP6006640B2 (ja) * | 2010-10-29 | 2016-10-12 | 株式会社ペルセウスプロテオミクス | 高い内在化能力を有する抗cdh3抗体 |
JP2014015396A (ja) | 2010-10-29 | 2014-01-30 | Perseus Proteomics Inc | 高い親和性を有する抗cdh3抗体 |
EP3536708A1 (en) | 2011-04-19 | 2019-09-11 | Pfizer Inc | Combinations of anti-4-1bb antibodies and adcc-inducing antibodies for the treatment of cancer |
JPWO2012176765A1 (ja) | 2011-06-24 | 2015-02-23 | 株式会社ペルセウスプロテオミクス | 抗ヒトp−カドへリン(cdh3)遺伝子組み換え抗体 |
AU2012376421A1 (en) * | 2012-04-04 | 2014-11-13 | Perseus Proteomics Inc. | Drug conjugate comprising anti-cdh3 (p-cadherin) antibody |
WO2013179174A1 (en) | 2012-05-29 | 2013-12-05 | Koninklijke Philips N.V. | Lighting arrangement |
JP6377601B2 (ja) * | 2013-02-15 | 2018-08-22 | 株式会社ペルセウスプロテオミクス | 抗cdh3ヒト化抗体、その薬剤コンジュゲート、及びそれらの使用 |
KR20170084202A (ko) * | 2014-11-14 | 2017-07-19 | 노파르티스 아게 | 항체 약물 접합체 |
EP3310813A1 (en) * | 2015-06-17 | 2018-04-25 | Novartis AG | Antibody drug conjugates |
US11605302B2 (en) | 2020-11-10 | 2023-03-14 | Rockwell Collins, Inc. | Time-critical obstacle avoidance path planning in uncertain environments |
-
2015
- 2015-11-13 KR KR1020177015786A patent/KR20170084202A/ko unknown
- 2015-11-13 EA EA201791050A patent/EA201791050A1/ru unknown
- 2015-11-13 WO PCT/IB2015/058801 patent/WO2016075670A1/en active Application Filing
- 2015-11-13 TW TW104137588A patent/TW201625692A/zh unknown
- 2015-11-13 PE PE2017000847A patent/PE20170912A1/es unknown
- 2015-11-13 EP EP15798251.3A patent/EP3218410B1/en active Active
- 2015-11-13 CA CA2967188A patent/CA2967188A1/en not_active Abandoned
- 2015-11-13 JP JP2017525950A patent/JP6831783B2/ja active Active
- 2015-11-13 SG SG11201703464UA patent/SG11201703464UA/en unknown
- 2015-11-13 MA MA040913A patent/MA40913A/fr unknown
- 2015-11-13 CN CN201580071419.9A patent/CN108064244B/zh active Active
- 2015-11-13 AU AU2015347015A patent/AU2015347015B2/en not_active Ceased
- 2015-11-13 US US14/940,961 patent/US10005836B2/en active Active
- 2015-11-13 CR CR20170200A patent/CR20170200A/es unknown
- 2015-11-13 TN TN2017000173A patent/TN2017000173A1/en unknown
- 2015-11-13 UY UY0001036401A patent/UY36401A/es not_active Application Discontinuation
- 2015-11-13 BR BR112017009813A patent/BR112017009813A2/pt not_active Application Discontinuation
- 2015-11-13 AR ARP150103709A patent/AR102649A1/es unknown
- 2015-11-13 MX MX2017006301A patent/MX2017006301A/es unknown
-
2017
- 2017-04-30 IL IL252015A patent/IL252015A0/en unknown
- 2017-05-12 PH PH12017500890A patent/PH12017500890A1/en unknown
- 2017-05-12 CO CONC2017/0004782A patent/CO2017004782A2/es unknown
- 2017-05-12 CL CL2017001217A patent/CL2017001217A1/es unknown
- 2017-05-12 GT GT201700102A patent/GT201700102A/es unknown
- 2017-06-05 EC ECIEPI201734845A patent/ECSP17034845A/es unknown
-
2018
- 2018-05-24 US US15/988,659 patent/US10626172B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
SG11201703464UA (en) | 2017-05-30 |
PE20170912A1 (es) | 2017-07-12 |
GT201700102A (es) | 2018-11-27 |
EP3218410A1 (en) | 2017-09-20 |
US20190119375A1 (en) | 2019-04-25 |
IL252015A0 (en) | 2017-06-29 |
EP3218410B1 (en) | 2024-03-27 |
KR20170084202A (ko) | 2017-07-19 |
AU2015347015A1 (en) | 2017-05-25 |
TN2017000173A1 (en) | 2018-10-19 |
US10626172B2 (en) | 2020-04-21 |
CN108064244B (zh) | 2021-09-17 |
AU2015347015A8 (en) | 2017-08-03 |
CL2017001217A1 (es) | 2017-12-22 |
MA40913A (fr) | 2017-09-20 |
WO2016075670A1 (en) | 2016-05-19 |
CA2967188A1 (en) | 2016-05-19 |
ECSP17034845A (es) | 2019-03-29 |
BR112017009813A2 (pt) | 2017-12-26 |
JP6831783B2 (ja) | 2021-02-17 |
CO2017004782A2 (es) | 2017-10-31 |
CN108064244A (zh) | 2018-05-22 |
JP2018501781A (ja) | 2018-01-25 |
MX2017006301A (es) | 2017-08-21 |
EA201791050A1 (ru) | 2017-09-29 |
US10005836B2 (en) | 2018-06-26 |
AR102649A1 (es) | 2017-03-15 |
PH12017500890A1 (en) | 2017-11-06 |
CR20170200A (es) | 2017-07-03 |
US20160137730A1 (en) | 2016-05-19 |
AU2015347015B2 (en) | 2019-02-14 |
TW201625692A (zh) | 2016-07-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UY36401A (es) | Conjugados anticuerpos-fármacos | |
UY37591A (es) | Conjugados de fármaco anticuerpo | |
CL2018002878A1 (es) | Composiciones y anticuerpos anti-tim-3. | |
PH12018500380A1 (en) | Anti-dll3 antibody drug conjugates and methods of use | |
PH12018501043A1 (en) | Site specific her2 antibody drug conjugates | |
CL2016002667A1 (es) | Anticuerpos anti-rnf43 novedosos y métodos para su uso | |
BR112017001588A2 (pt) | conjugados de anticorpo/fármaco anti-cdh6 | |
BR112017007170A2 (pt) | anticorpos anti-ox40 humanizados e suas utilizações | |
PE20150892A1 (es) | Anticuerpos anti-notch y conjugados de anticuerpo-farmaco | |
MX2018006249A (es) | Nuevos anticuerpos anti-emr2 y metodos de uso. | |
AR101671A1 (es) | Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso | |
ECSP21044421A (es) | Anticuerpos anti-pmel17 y conjugados de los mismos | |
MX2018007817A (es) | Nuevos anticuerpos anti-mmp16 y metodos para su uso. | |
MX2018007818A (es) | Anticuerpos dirigidos contra upk1b novedosos y metodos para su uso. | |
MX2018013484A (es) | Nuevos anticuerpos anti-tnfrsf21 y modos de uso. | |
AR107223A1 (es) | Anticuerpos dirigidos contra upk1b y métodos para su uso |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
109 | Application deemed to be withdrawn |
Effective date: 20220712 |